In this issue:
Nab-paclitaxel has similar efficacy to paclitaxel but greater toxicity in metastatic UC
KEYNOTE-426 results support front-line pembrolizumab plus axitinib in advanced RCC
De-escalated dosing of bone-targeting agents is non-inferior to standard dosing
Biomarkers of axitinib/pembrolizumab treatment response in RCC
ZEN-3694 plus enzalutamide in patients with metastatic CRPC
Smoking increases postoperative mortality in patients with UC undergoing radical cystectomy
A risk calculator predicting recurrence in lymph node metastatic penile cancer
Patients with FGFR3 mutant bladder cancer are suitable for adjuvant anti-FGFR3 treatment
NIMBUS fails to prove non-inferiority of a reduced BCG instillation protocol
Age no barrier to immunotherapy in RCC and UC
Cabazitaxel is safe and efficacious in elderly patients with CRPC
Please login below to download this issue (PDF)